BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin widens to -62.5%

Net margin was -62.5% in Q2 FY2026, up 102.1 pp from a year earlier. On a trailing-twelve-month basis it was -97.6%, up 231.6 pp year over year. Over 3 fiscal years it widened by 474.4 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 13 analysts of -43.9% for the fiscal year ending Dec 2026, up from -145.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-62.5%+21.9 pp QoQ
Last fiscal yearDec 2025
-145.3%+96.2 pp YoY
LTMJun 2026
-97.6%+231.6 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+102.1 pp+115.2 pp+13.1 pp
1 year+96.2 pp+101.3 pp+5.2 pp
3 years+474.4 pp+171.0 pp-303.4 pp
5 years+186.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-145.3%
Year-over-year change
+96.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How BBIO compares with its peers on the latest reported figures

  • BBIO's LTM Jun 2026 net margin of -97.6% is the 8th highest of the 11 companies compared; the peer median is -37.8%.
  • Its year-over-year change of +231.6 pp is the highest of 9, against a peer median of -13.6 pp.
  • Over three fiscal years its change of +474.4 pp compares with a peer median of +117.5 pp.
BBIO Competitors Peer median
Net Margin for BBIO and competitors
Company Period LTM level YoY 3-year change
ASNDAscendis Pharma A/SLTM Sep 202673.7% +109.7 pp+1108.0 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202616.8% +29.8 pp+117.5 pp
PTCTPTC Therapeutics, Inc.LTM Jun 2026-3.8% -39.5 pp+119.4 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-11.9% -28.8 pp+4.1 pp
TVTXTravere Therapeutics, Inc.LTM Sep 2026-18.7% +1.7 pp+249.2 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-56.9% -30.4 pp+5.6 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-91.0% +2.0 pp+109.3 pp
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-97.6% +231.6 pp+474.4 pp
MAZEMaze Therapeutics, Inc.LTM Mar 2026-612.7% -643.7 pp—
DNLIDenali Therapeutics Inc.LTM Jun 2026-14191.2% ——
SRRKScholar Rock Holding CorporationLTM Sep 2026-72563.2% ——
Peer median (excluding BBIO) -37.8%-13.6 pp+117.5 pp

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue69.72M77.65M9.3M221.9M502.08M
Cost of Revenue3.11M3.43M2.45M3.88M28.27M
Gross Profit66.6M74.21M6.86M218.02M473.81M
Gross Margin95.5%95.6%73.7%98.3%94.4%
Research & Development451.02M399.46M455.71M506.46M477.54M
Selling, General & Admin192.21M143.19M150.59M288.93M555.14M
Operating Expenses643.23M586.42M614.23M811M1.04B
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
EBITDA(533.83M)(397.44M)(565.47M)(436.83M)(676.45M)
EBITDA Margin-765.7%-511.9%-6078.3%-196.9%-134.7%
Operating Income(576.63M)(512.2M)(607.37M)(592.97M)(569.09M)
Operating Margin-827.1%-659.6%-6528.8%-267.2%-113.3%
Interest Income1.13M7.54M18.04M17.25M19.85M
Interest Expense46.78M80.44M81.29M99.29M53.1M
Other Income / Expenses(9.82M)27.55M(45.88M)50.78M(165.9M)
Income Before Tax(586.45M)(484.65M)(653.25M)(542.19M)(734.99M)
Pre-Tax Margin-841.2%-624.2%-7021.9%-244.3%-146.4%
Income Tax Expense0001.15M555K
Net Income(562.54M)(481.18M)(643.2M)(535.76M)(729.31M)
Net Margin-806.9%-619.7%-6913.9%-241.4%-145.3%
EPS (Basic)(3.90)(3.35)(3.95)(2.88)(3.79)
EPS (Diluted)(3.90)(3.35)(3.95)(2.88)(3.79)
Weighted Avg Shares144.36M147.47M162.79M186.08M197.24M
Weighted Avg Shares (Diluted)144.36M147.47M162.79M186.08M197.24M

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.